ArticleApoptosis : an international journal on programmed cell death2026
Ferroptosis dysregulation, mitochondrial dysfunction, and iron metabolism alterations are correlated with aggressiveness in uveal melanoma.
Article in Apoptosis : an international journal on programmed cell death, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To elucidate the dysregulation of ferroptosis in uveal melanoma (UM), a comprehensive understanding is required of the expression patterns of ferroptosis-related genes, their association with key driver mutations and clinicopathological features, and their prognostic significance in UM patients. We analyzed tumor tissues from 56 UM enucleated eyeballs using qRT-PCR, immunohistochemistry, and western blotting to quantify ferroptosis-associated genes (SLC7A11, SLC3A2, GPX4, TFR1, CISD1, ACSL4, LPCAT3). Serum glutathione (GSH), ferritin, and lipid peroxidation assays were performed. These data were integrated with clinicopathologic parameters, driver mutations, mitochondrial ultrastructure, mtDNA copy number, and clinical outcomes. Independent validation was performed using TCGA-UM data. SLC7A11 and GPX4 were significantly upregulated in BAP1-mutant tumors. High expression of these markers was associated with reduced metastasis-free and overall survival (p < 0.05). TFR1 was downregulated in BAP1-deficient tumors, and low TFR1 protein levels independently predicted poor prognosis (p < 0.01). Serum GSH was decreased in UM patients, despite upregulation of GSH-related genes, indicating systemic oxidative imbalance. Downregulation of CISD1, ACSL4, and LPCAT3 were linked to alteration in mitochondria morphology, elevated mtDNA content, and unfavorable prognosis. These findings indicate that ferroptosis dysregulation is a hallmark of aggressive UM. SLC7A11, GPX4, and TFR1 represent clinically relevant biomarkers and potential therapeutic targets.
Indexed as
Identifiers
41518375What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.